The Drug Regulatory Authority of Pakistan (DRAP) has marked a significant milestone as its Karachi laboratory secured prequalification from the World Health Organization (WHO). This achievement represents a crucial step in elevating the standards of drug testing within Pakistan, ensuring that pharmaceutical products meet international quality benchmarks. The WHO prequalification is a rigorous process that validates the lab’s technical competence and compliance with global testing protocols.
In a significant development for Pakistan’s healthcare sector, this recognition not only bolsters the credibility of DRAP’s regulatory framework but also facilitates greater confidence among local and international stakeholders in the safety and efficacy of medicines tested in the country. The enhanced testing capabilities can lead to improved public health outcomes by preventing substandard or counterfeit drugs from entering the market. Moreover, it positions Pakistan to better participate in global pharmaceutical supply chains.
Meanwhile, the WHO prequalification can attract further investment and collaboration opportunities for Pakistan’s pharmaceutical industry, fostering innovation and quality assurance. This accomplishment underscores the government’s commitment to strengthening regulatory institutions and protecting consumer health. As drug safety remains a critical concern worldwide, DRAP’s Karachi lab sets a precedent for other regional laboratories aspiring to meet international standards.
